Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
t-cell symbols : Abbv save search
AbbVie and Umoja Biopharma Announce Strategic Collaboration to Develop Novel In-Situ CAR-T Cell Therapies
Published: 2024-01-04 (Crawled : 00:00) - biospace.com/
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -0.34%
H: 0.0%
C: 0.0%
abbvie cell biopharma collaboration car-t
T-cell lymphoma Market 2026, Growing Geriatric Population to Boost Growth - Technavio
Published: 2022-09-26 (Crawled : 06:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 5.77%
H: 0.0%
C: -2.27%
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: -1.15%
H: 0.0%
C: -2.43%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -2.04%
H: 0.82%
C: 0.2%
BAX | $39.47 -0.45% 0.0% 2.8M
|
Health Technology
|
| O: -0.45%
H: 0.6%
C: -0.45%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -0.69%
H: 0.51%
C: -0.61%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -2.29%
H: 0.35%
C: -0.67%
BIIB | $194.39 2.03% 1.99% 1.6M
|
Health Technology
|
| O: -0.17%
H: 1.2%
C: -0.86%
AUTL | $4.51 -6.04% -6.43% 1.4M
|
Health Technology
|
| O: 2.94%
H: 1.43%
C: -0.48%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -1.52%
H: 0.48%
C: -1.36%
growing t-cell growth market
Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Research Report 2021: Analysis of Yescarta, Tecartus, Kymriah, Breyanzi, & Abecma
Published: 2021-12-24 (Crawled : 14:00) - prnewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
| Email alert
Add to watchlist
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
| Email alert
Add to watchlist
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
| Email alert
Add to watchlist
CYAD | $0.47 -12.49% 49K
|
Health Technology
| Email alert
Add to watchlist
yescarta research kymriah cel therapy t-cell
Global CAR-T Cell Therapy Markets to 2026: Rising Clinical Trials and Development of New and Effective Therapy Options
Published: 2021-09-28 (Crawled : 16:00) - prnewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: -0.12%
H: 1.77%
C: -0.99%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.16%
H: 0.04%
C: -0.51%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.04%
H: 0.5%
C: -0.18%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -0.09%
H: 0.93%
C: -0.26%
SGMO | $0.5143 6.02% 5.68% 1M
|
Health Technology
|
| O: -1.12%
H: 0.52%
C: -2.17%
AUTL | $4.51 -6.04% -6.43% 1.4M
|
Health Technology
|
| O: -2.67%
H: 1.27%
C: -5.48%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.38%
H: 1.16%
C: -0.01%
clinical trials therapy car-t trials trial t-cell
Clinical Trial of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma (B-NHL) Published in The Lancet
Published: 2021-09-09 (Crawled : 14:15) - biospace.com/
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -0.83%
H: 0.27%
C: -1.98%
GMAB | $28.72 1.38% 1.36% 360K
|
Health Technology
|
| O: -1.2%
H: 0.95%
C: -0.77%
trial t-cell lancet
AbbVie and Caribou Biosciences Announce Collaboration and License Agreement for CAR-T Cell Products
Published: 2021-02-10 (Crawled : 14:00) - biospace.com/
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.55%
H: 0.14%
C: -1.82%
collaboration car-t license t-cell announces collaboration bioscience
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.